 |
148 Diseases |  |
56 Trials |
|
56 Trials |  |
3630 News |  |
| «12345678910111213...4041» |
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
New trial: Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia (clinicaltrials.gov) - Jan 1, 2024
P=N/A, N=220, Not yet recruiting, Sponsor: Medanta, The Medicity, India
- | Januvia (sitagliptin) / Merck (MSD)
Journal: miR-23b-3p Ameliorates LPS-Induced Pulmonary Fibrosis by Inhibiting EndMT via DPP4 Inhibition. (Pubmed Central) - Dec 27, 2023
In our mouse model of LPS-induced pulmonary fibrosis, miR-23b-3p and a DPP4 inhibitor (sitagliptin) individually alleviated LPS-induced EndMT progression and pulmonary fibrosis, and their combined use achieved the strongest remission effect. To sum up, miR-23b-3p alleviates EndMT in pulmonary fibrosis by inhibiting the expression of DPP4.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms. (Pubmed Central) - Dec 22, 2023
were restored with ST treatment. Based on that, our study revealed for the first time the hepatoprotective effect of ST that is mediated by controlling inflammation, oxidative stress, and mTOR/NF-?B/NLRP3 signaling.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Increased Thyroid DPP4 Expression is Associated with Inflammatory Process in Patients with Hashimoto's Thyroiditis. (Pubmed Central) - Dec 21, 2023
Inhibition of lymphocyte DPP4 activity reduced the production of inflammatory factors in co-cultured thyroid cells. Therefore, inhibition of DPP4 may have a beneficial effect by alleviating inflammatory reactions in HT patients.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Journal: Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes. (Pubmed Central) - Dec 21, 2023
Therefore, inhibition of DPP4 may have a beneficial effect by alleviating inflammatory reactions in HT patients. Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.
- | Trial completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Dec 15, 2023
P=N/A, N=150, Active, not recruiting, Sponsor: Weill Cornell Medical College in Qatar
Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes. Trial completion date: Oct 2023 --> Oct 2024
- | Januvia (sitagliptin) / Merck (MSD)
Journal, Machine learning: Identification of active compounds as novel dipeptidyl peptidase-4 inhibitors through machine learning and structure-based molecular docking simulations. (Pubmed Central) - Dec 15, 2023
Structure-based virtual screening was performed along with positive control sitagliptin to obtain more specific and selective leads for DPP4...Therefore, Z-614 showed a high deviation in the backbone. This combined approach (ML and structure-based) study reported that Z-997 binds most stably to DPP4 in their catalytic pocket with a binding free energy of -70.3?kJ/mol, suggesting its therapeutic potential as a treatment option for T2DM disease.Communicated by Ramaswamy H. Sarma.
- | Januvia (sitagliptin) / Merck (MSD)
Journal, IO biomarker: Sitagliptin Induces Tolerogenic Human Dendritic Cells. (Pubmed Central) - Dec 9, 2023
A Western blot analysis showed that sitagliptin inhibited p65 expression of NF-kB and p38MAPK during the maturation of MoDCs. In conclusion, sitagliptin induces differentiation of tolerogenic DCs, and the effect is important when considering sitagliptin for treating autoimmune diseases and allotransplant rejection.
- | Jakafi (ruxolitinib) / Novartis, Incyte, epothilone D (BMS-241027) / BMS, Januvia (sitagliptin) / Merck (MSD)
Journal: Rhodium-Catalyzed Allylic Addition as an Atom-Efficient Approach in Total Synthesis. (Pubmed Central) - Dec 8, 2023
The potential of the addition of nitrogen pronucleophiles to allenes was demonstrated in the total syntheses of Cusparein, Angusterein, Cermicin C, Senepodin G, Homoproline, Pipecolinol, Coniceine, Coniine, Ruxolitinib, Sitagliptin, Abacavir, Glucokinase activators, and Chaetominine. All of these examples testify to the wide applicability of the Rh-catalyzed addition of pronucleophiles to allenes or alkynes in target-oriented synthesis, and in this Account we summarize our contribution.
- | metformin / Generic mfg.
Journal: Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis (Pubmed Central) - Dec 8, 2023
All of these examples testify to the wide applicability of the Rh-catalyzed addition of pronucleophiles to allenes or alkynes in target-oriented synthesis, and in this Account we summarize our contribution. Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation. (Pubmed Central) - Dec 6, 2023
The efficacy of several solutions was proven, but could not be fully disclosed due to Intellectual Property Protection policy of Zentiva. Instead, a brief review of recently published strategies to cope with N-nitrosamine contamination is presented.
- | Journal: Interactive effect of oral anti-hyperglycaemic or anti-hypertensive drugs on the inhibitory and bactericidal activity of first line anti-TB drugs against M. tuberculosis. (Pubmed Central) - Dec 4, 2023
All the six anti-HT drugs, namely, Atenolol, Hydrochlorothiazide, Ramipril, Valsartan, Nifedipine and Verapamil exerted either 'additive'/'synergistic' or 'no effect' on the activities of anti-TB drugs. These findings may help clinicians to select safe and helpful anti-HG or anti-HT drugs for TB patients, if, suffering with diabetes or hypertension like co-morbidities and receiving DOTs (a set regimen for the treatment of TB based on the WHO guidelines).
- || DA-1241 - Dong / A
Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH (clinicaltrials.gov) - Nov 27, 2023
P2, N=87, Recruiting, Sponsor: NeuroBo Pharmaceuticals Inc.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Review, Journal, Real-world evidence, Real-world: Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 21, 2023
Empagliflozin was the most pancreatitis-risk SGLT-2 inhibitor [PRR?=?4.0, LB ROR?=?3.5, IC?=?1.8]...Evidence from the post-marketing safety data analysis identified a strong association between incretin mimetics and pancreatic events. Fewer events in RCTs may justify insignificant meta-analysis results.
- | DA-1241 - Dong / A
Phase classification: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH (clinicaltrials.gov) - Nov 18, 2023
P2, N=87, Recruiting, Sponsor: NeuroBo Pharmaceuticals Inc.
Fewer events in RCTs may justify insignificant meta-analysis results. Phase classification: P2a --> P2
- | Januvia (sitagliptin) / Merck (MSD)
Journal: SOLID-STATE PHASE TRANSFORMATION OF MONOHYDRATE AND ANHYDROUS FORM II OF SITAGLIPTIN PHOSPHATE INTO A NOVEL ANHYDROUS FORM IV - SOLVENT-DRIVEN, TEMPERATURE-INDUCED AND STRESS TESTINGS. (Pubmed Central) - Nov 17, 2023
This research corrects the record with an accurate chemical composition of the anhydrous form IV of sitagliptin phosphate that was previously regarded as a hemiethanolate. In addition, the crystal structure of anhydrous form II of sitagliptin phosphate has been solved and reported for the first time.
- || Review, Journal: Potentially active compounds that improve PAD through angiogenesis: A review. (Pubmed Central) - Nov 15, 2023
This paper focuses on the therapeutic effect of natural products (Salidroside, Astragaloside IV, etc.) and synthetic compounds (Cilostazol, Dapagliflozin, etc.)...Overall, these exogenous compounds have promising therapeutic potential for PAD. This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model. (Pubmed Central) - Nov 15, 2023
This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients. Subsequently, the animals were treated with SGLT2-i (empagliflozin, 25
- | dapagliflozin/sitagliptin / AstraZeneca, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Journal, Real-world evidence, Real-world: The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population. (Pubmed Central) - Nov 13, 2023
These findings highlight the potential benefits of this combination therapy in managing T2DM and pave the way for optimized treatment strategies and improved patient outcomes in the Indian healthcare landscape. Clinicians may consider dapagliflozin-sitagliptin FDC as a viable treatment option for T2DM patients.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Sitagliptin Extends Lifespan of Caenorhabditis elegans by Inhibiting IIS and Activating DR-like Signaling Pathways. (Pubmed Central) - Nov 12, 2023
Clinicians may consider dapagliflozin-sitagliptin FDC as a viable treatment option for T2DM patients. Our work may provide a theoretical basis for the development of anti-T2D drugs as anti-aging drugs, especially for the treatment of age-related disease in diabetic patients.
- | Bilessglu (chiglitazar) / Chipscreen
Journal: Personalized glucose-lowering effect of chiglitazar in type 2 diabetes. (Pubmed Central) - Nov 9, 2023
To identify patients who would gain the most glycemic control benefit from chiglitazar, we developed a machine learning model, ML-PANPPAR, which demonstrated robust performance using sex, BMI, HbA, HDL, and fasting insulin. The phenomapping-derived tool successfully identified chiglitazar responders and enabled personalized drug allocation in patients with drug-na
- ||| Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. (clinicaltrials.gov) - Nov 8, 2023
P1, N=58, Completed, Sponsor: Galenicum Health
- || Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions. (clinicaltrials.gov) - Nov 8, 2023
P1, N=48, Completed, Sponsor: Galenicum Health
- ||| Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. (clinicaltrials.gov) - Nov 8, 2023
P1, N=58, Completed, Sponsor: Galenicum Health
- || Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions. (clinicaltrials.gov) - Nov 8, 2023
P1, N=48, Completed, Sponsor: Galenicum Health
- | Reimbursement, US reimbursement, Journal, HEOR, Medicare, Real-world evidence, Medicaid, Real-world: Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations. (Pubmed Central) - Nov 3, 2023
The phenomapping-derived tool successfully identified chiglitazar responders and enabled personalized drug allocation in patients with drug-na Materials & A scoping review was completed in MEDLINE/PubMed to evaluate the availability of comparative RWE investigations conducted among Medicare-eligible patient populations in the
- | Januvia (sitagliptin) / Merck (MSD)
New P3 trial: The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy (clinicaltrials.gov) - Nov 3, 2023
P3, N=46, Completed, Sponsor: Ain Shams University
- Januvia (sitagliptin) / Merck (MSD)
Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6383;
P3
190 eligible p ts (18-60 years) were planned randomly assigned in a 1:1 ratio to either a sitagliptin group (600mg sitagliptin taken orally every 12 hours on day -1 to +14, plus conventional prophylaxis including Cyclosporin A(CsA)/ tacrolimus (FK506) , MTX, MMF and ATG ) and a conventional prophylaxis control group ( CsA/FK506 , MTX, MMF and ATG )...Furthermore, sitagliptin is ready availab le , eas y of administration, safe, and relatively inexpensive . It remains to be followed up whether it would increase infection and relapse or improve the prognosis of patients after allo-HSCT.
- ||| dapagliflozin/metformin/sitagliptin (GMRx4) / George Medicines
Trial completion date, Trial initiation date, Trial primary completion date: PiVOT: Polypill Versus Metformin in New Onset Type 2 Diabetes (clinicaltrials.gov) - Oct 30, 2023
P2, N=334, Not yet recruiting, Sponsor: George Medicines PTY Limited
It remains to be followed up whether it would increase infection and relapse or improve the prognosis of patients after allo-HSCT. Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Aug 2023 --> Jan 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea. (Pubmed Central) - Oct 28, 2023
The usage of empagliflozin in diabetic CKD patients shows a significant reduction in many adverse outcomes compared to sitagliptin, but with an increased risk of genital tract infections. These findings provide evidence for future clinical decision-making around the use of empagliflozin in Asian CKD patients.
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion date: Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (clinicaltrials.gov) - Oct 27, 2023
P4, N=20, Recruiting, Sponsor: University of Pennsylvania
These findings provide evidence for future clinical decision-making around the use of empagliflozin in Asian CKD patients. Trial completion date: Feb 2024 --> Dec 2024
- | Januvia (sitagliptin) / Merck (MSD)
Journal, Bariatric surgery: Differential effect of gastric bypass versus sleeve gastrectomy on insulinotropic action of endogenous incretins. (Pubmed Central) - Oct 23, 2023
Trial completion date: Feb 2024 --> Dec 2024 After GB, increasing incretin activity augments prandial ?-cell response whereas the ?-cell sensitivity to increasing plasma concentrations of endogenous incretin is diminished.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Environmental friendly protocol for the determination of sitagliptin phosphate in pharmaceutical preparations and biological fluids using L-tyrosine as a fluorescence probe. (Pubmed Central) - Oct 22, 2023
The method was validated usin ICH guidelines and profitably applied for the content uniformity test, ensuing in a high percent recovery and small relative standard deviation. The proposed approach is effortless, susceptible, selective, economic, and provides a high precision and accuracy, and can be used to determine sitagliptin phosphate in pharmaceutical industry.
- ||| Bilessglu (chiglitazar) / Chipscreen
P3 data, Journal: Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials. (Pubmed Central) - Oct 19, 2023
Chiglitazar shows promising efficacy for glycemic control in patients with T2DM associated with MetS or IR. Further prospective trials are required to validate these findings.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Experimental and modeling of solubility of sitagliptin phosphate, in supercritical carbon dioxide: proposing a new association model. (Pubmed Central) - Oct 16, 2023
Further prospective trials are required to validate these findings. The measured solubilities were in the range of 3.02
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Microbial-host-isozyme: unveiling a new era in microbiome-host interaction. (Pubmed Central) - Oct 14, 2023
Among them, DPP4 isozymes degrade GLP-1, explaining variable responses to sitagliptin...However, the complex nature of gut symbiotic bacteria requires further research to understand MHI mechanisms, regulatory roles, and interactions with the host. Precise interventions in gut microbiota offer personalized approaches to metabolic diseases.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Journal: A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation. (Pubmed Central) - Oct 9, 2023
Conclusion The combination of sitagliptin and metformin showed enhanced benefits in lipid profile management compared to the combination of empagliflozin and metformin in patients with T2D. This discovery underscores the need for holistic treatment modalities that factor in blood glucose levels and cardiovascular health.
- | metformin / Generic mfg.
Journal: Interactions of Metformin and Other Medications in Reducing the Odds of Age-Related Macular Degeneration in a Diabetic Cohort. (Pubmed Central) - Oct 2, 2023
This discovery underscores the need for holistic treatment modalities that factor in blood glucose levels and cardiovascular health. We believe our results bring us one step closer to finding an optimal effective hypoglycemic regimen that also protects against AMD development in diabetic patients.
- | Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal, HEOR: The Use of Rescue Insulin in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (Pubmed Central) - Sep 27, 2023
Wanting to use non-insulin strategies to improve glycemia was commonly reported, although multiple factors likely contributed to not using rescue insulin. These findings highlight the persistent challenge of intensifying type 2 diabetes treatment with insulin, even in a clinical trial.
- |||| DA-1241 - Dong / A
New P2 trial, New P2a trial: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH (clinicaltrials.gov) - Sep 26, 2023
P2a, N=87, Recruiting, Sponsor: NeuroBo Pharmaceuticals Inc.
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Trial completion date: SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) (clinicaltrials.gov) - Sep 25, 2023
P4, N=76, Completed, Sponsor: Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
These findings highlight the persistent challenge of intensifying type 2 diabetes treatment with insulin, even in a clinical trial. Recruiting --> Completed | Trial completion date: Jul 2024 --> Aug 2023
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Elucidating sulfate radical-induced oxidizing mechanisms of solid-phase pharmaceuticals: Comparison with liquid-phase reactions. (Pubmed Central) - Sep 20, 2023
Therefore, some post-treatment strategies need to be considered during practical applications of SO-based technologies in remediating different phases of micropollutants. This work has environmental implications for understanding the comparative transformation mechanisms of pharmaceuticals by SO oxidation in remediating the contaminated solid and aqueous matrices.
- ||| Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Journal, Adverse events: Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. (Pubmed Central) - Sep 11, 2023
Thus, metabolites reporting on dysregulated mitochondrial fatty acid oxidation are higher in individuals with T2D who experience subsequent MACE. These biomarkers may improve CV risk prediction models, be therapy responsive, and highlight emerging risk mechanisms.
- | Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Journal: Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up. (Pubmed Central) - Sep 9, 2023
These biomarkers may improve CV risk prediction models, be therapy responsive, and highlight emerging risk mechanisms. Of the 138 enrolled patients (49.30% male, mean age 57.86
- || Januvia (sitagliptin) / Merck (MSD)
PK/PD data, Preclinical, Journal: In vitro study and pharmacokinetic evaluation of sitagliptin phosphate enantiomers in rat plasma. (Pubmed Central) - Sep 7, 2023
A glucose uptake assay was used to assess enantiomers in 3T3-L1 cell lines through flow cytometry. Investigation of the pharmacokinetic impacts of sitagliptin phosphate racemic enantiomers in rat plasma revealed notable contrasts in R and S enantiomers in female albino Wistar rats, suggesting enantioselectivity for sitagliptin phosphate.
- | Brenzavvy (bexagliflozin) / TheracosBio
Journal: Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes. (Pubmed Central) - Aug 31, 2023
Investigation of the pharmacokinetic impacts of sitagliptin phosphate racemic enantiomers in rat plasma revealed notable contrasts in R and S enantiomers in female albino Wistar rats, suggesting enantioselectivity for sitagliptin phosphate. No abstract available
- || Januvia (sitagliptin) / Merck (MSD)
Review, Journal: Graft-versus-host disease: teaching old drugs new tricks at less cost. (Pubmed Central) - Aug 25, 2023
In this review article, we summarize the latest evidence on how we can continue to repurpose drugs for GVHD prophylaxis and treatment. Drugs covered by our review include those that have been FDA approved for other uses for at least 15 years (since 2008); thus, they are likely to have generic equivalents available now or in the near future.
- | Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe, Januvia (sitagliptin) / Merck (MSD)
Journal: Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus. (Pubmed Central) - Aug 24, 2023
A total of 14 patients (7%) had hyperamylasemia but the prevalence of hyperamylasemia did not differ between DPP4i users and nonuser (6/107 vs. 8/93, P = 0.42). Asymptomatic hyperamylasemia is not uncommon in South Indian T2DM patients but is not associated with the use of DPP4i.
- | Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. (Pubmed Central) - Aug 22, 2023
Asymptomatic hyperamylasemia is not uncommon in South Indian T2DM patients but is not associated with the use of DPP4i. Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction.
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Surgery: SiCa-Flam: Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass (clinicaltrials.gov) - Aug 22, 2023
P=N/A, N=20, Completed, Sponsor: University Hospital Muenster
Empagliflozin was superior to sitagliptin in relation to glycemic control, weight, and systolic/diastolic blood pressure reduction. Active, not recruiting --> Completed